Access program for Orca-T in advanced blood cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This program gives patients with advanced blood cancers access to Orca-T, a special cell therapy, when their prepared dose couldn't be used for routine reasons. It's a way to receive treatment that might otherwise be discarded, as long as their doctor confirms it's safe and appropriate.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your doctor must have already prescribed Orca-T for you.
- The Orca-T dose made for you did not pass quality checks or was past its expiration date.
- Both your doctor and the manufacturer agree it's okay to use this product for you anyway.
- Making a new batch of Orca-T for you is not possible or not safe, according to your doctor.
- Your doctor must confirm you are well enough and stable to receive the treatment.
- You must not have other medical conditions that could make the treatment unsafe, in your doctor's opinion.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy, orca-t, given after a lower-intensity chemo and radiation regimen for people with acute myeloid leukemia, mixed phenotype leukemia, or myelodysplastic syndrome. It aims to help patients who cannot tolerate full-intensity transplant conditioning.
This Phase 1 trial studies Orca-Q to see if it is safe and works when added around the time of an allogeneic (donor) stem cell transplant for certain blood cancers. If you qualify, the study may offer a new option for managing the transplant immune response.
This trial tests a new approach for people with advanced blood cancers who are getting a donor stem cell transplant. It aims to improve outcomes by using your own regulatory T cells along with the donor cells.
This trial tests a new way to prepare donor stem cells before a transplant for children and young adults with blood cancers. The goal is to make the transplant safer and more effective, potentially reducing complications like graft-versus-host disease.
This early-phase study tests ORIC-114 to treat advanced solid tumors that have certain EGFR or HER2 genetic changes, often found in lung and breast cancers. It may help by targeting those specific cancer mutations, especially when standard treatments no longer work or aren’t tolerated.
This trial tests a new cell therapy called obecabtagene autoleucel (a 'living drug' made from your own immune cells) for people with a type of blood cancer (B-cell ALL) that has responded to initial treatment but may still have tiny traces. The goal is to see if it can prevent relapse after remission.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.